Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2882406 | The Annals of Thoracic Surgery | 2007 | 8 Pages |
Abstract
Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Oliver MRCS, Kaushik MS, MRCS, Vassilis MD, Lisa BSc (Hons), Sukhmeet BSc (Hons), Kokotsakis MD, Ara FMedSci, KBE, Thanos MD, PhD,